Alpha-Methyltyrosine clinical trials
Also written L1-79.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
Counted the way a researcher would: Alpha-Methyltyrosine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses alpha-Methyltyrosine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 3 Oct 1979 · DEMSER · NDA 017871 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 4
Yamo Pharmaceuticals LLC (2) · Tyme, Inc (2) · Sarcoma Oncology Research Center, LLC (1) · University of Bern (1) · Georgetown University (1) · Yale University (1) · Bausch Health Americas, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses alpha-Methyltyrosine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for SarcomaActive, not recruitingPhase 2Sarcoma Oncology Research Center, LLCNCT03778996Written as Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
- Safety of L1-79 in Adolescent and Adult Males With AutismCompletedPhase 2Yamo Pharmaceuticals LLCNCT02947048Written as L1-79
- A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum DisorderCompletedPhase 2Yamo Pharmaceuticals LLCNCT05067582Written as L1-79
- Oral SM-88 in Patients With Metastatic HR+/HER2- Breast CancerTerminatedPhase 2Georgetown UniversityNCT04720664Written as SM-88
- Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PETTerminatedNot applicableYale UniversityNCT02152670Written as Alpha Methyl Para Tyrosine (AMPT)
- Study of SM-88 in Advanced CancersWithdrawnPhase 1/2Tyme, IncNCT02562612Written as SM-88
- Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial SyndromeTerminatedPhase 2Bausch Health Americas, Inc.NCT01127503Written as Metyrosine
- Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate CancerCompletedPhase 1/2Tyme, IncNCT02796898Written as SM88 (Cohort 1)
- Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy ControlsSuspendedNot applicableUniversity of BernNCT02179814Written as AMPT/ Demser
Codes
What other systems call alpha-Methyltyrosine · ClinicalTrials.gg INT008723
- MeSH (NLM) D019805alpha-MethyltyrosineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DOQ0J0TPF7METYROSINEConfirmed FDA, NLM
- RxNorm 266604One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D019805 | alpha-Methyltyrosine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DOQ0J0TPF7 | METYROSINE | Confirmed FDA, NLM |
| RxNorm | 266604 | — | One source FDA |
Also registered as racemetyrosine (UNII X88TTO174Z).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.